Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Biomarkers in Gastrointestinal Cancer: Expert Perspectives and Guidance for Individualized Treatment
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Seagen Inc.
Turning Point Therapeutics, Inc.
John L. Marshall, MD
Michael J. Pishvaian, MD, PhD
Manish A. Shah, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations for molecular profiling in GI malignancies to guide treatment selection
  • Plan individualized therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients on tumor molecular profile and how this information will guide therapy decisions to optimize outcomes and quality of life
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Merck, Pfizer, and Taiho; has served on the Advisory Board for Caris; and has received salary from Indivumed.
Michael J. Pishvaian, MD, PhD

Associate Professor
Sidney Kimmel Cancer Center
Johns Hopkins University
Director
Clinical Research, GI and Phase I Oncology in the National Capital Region
Johns Hopkins at Sibley Memorial Cancer Center
Washington, DC

Michael J. Pishvaian, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Merck, Novartis, and Pfizer; has received funds for research support paid to his institution from Arcus Bio, Ideaya, Merck, Novartis, Pfizer, Repare Tx, Seattle Genetics, Takeda, Tesaro, and Tizonia; has ownership interests in Perthera; and holds intellectual property rights with AbbVie and Perthera.
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief,
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
 New York, New York

Manish A. Shah, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb and Merck.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Brian Purves, PharmD, MBA
Brian Purves, PharmD, has disclosed that he has previously received salary from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal malignancies.

Goal

The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Biomarkers in Gastrointestinal Cancer: Expert Perspectives and Guidance for Individualized Treatment
  • CME

Loading...
In this on-demand webcast from a live symposium, oncology John L. Marshall, MD; Michael J. Pishvaian, MD, PhD; and Manish A. Shah, MD discuss the perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies
John L. Marshall, MD
Michael J. Pishvaian, MD, PhD
Manish A. Shah, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023

Related Content

Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: February 2, 2023

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Updated data from the CheckMate 649 study of nivolumab + chemotherapy for advanced gastric/GEJ cancer and esophageal adenocarcinoma, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

MOUNTAINEER concordance analysis between breast and gastric algorithms for HER2 testing in mCRC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Seagen Inc.
Turning Point Therapeutics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings